Zentriforce Pharma

Executive Summary

Zentriforce Pharma is a Germany-based analytical service provider specializing in the characterization of complex biopharmaceuticals and advanced therapy medicinal products (ATMPs). Founded in 2017 and headquartered in Munich, the company offers expert services using sophisticated techniques such as analytical ultracentrifugation (AUC) and asymmetrical flow field-flow fractionation (AF4). Its core focus areas include gene therapy product analysis, biosimilarity studies, and peptide characterization. By providing high-quality analytical data, Zentriforce supports pharmaceutical companies in regulatory filings and quality control, positioning itself as a key partner in the biologics and gene therapy value chain. The company operates in a growing market driven by increasing complexity of biologics and stringent regulatory requirements.

Upcoming Catalysts (preview)

• Q3 2026Major Contract Win with Top Pharma70% success
• Q4 2026Expansion into Cell & Gene Therapy Analytical Services60% success
• Q2 2026ISO/IEC 17025 Accreditation Announcement80% success